Vaxcyte, Inc. (PCVX)
NEUTRALFundamental
37
Precio
$61.31
Capitalización Bursátil
$9.16B
Parte 1 · Cuánto vale la empresa
Resumen
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
0
Ejercicio cerrado el 31/12/2025
Beneficio Neto
$-767M
Ejercicio cerrado el 31/12/2025
Flujo de Caja Libre
$-669M
Patrimonio Neto Total
$2.69B
Pasivo Total
$317M
Ratio de Liquidez
5.72
Cobertura de Intereses
-
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$109.00
Precio Actual
$61.31
Margen de Seguridad
+43.8%
Rango de Valor Justo
$103.55 - $114.45
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-28.5%
Ratio P/B
3.34
P/FCF
-
Margen Bruto
-
ROIC
-32.1%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-32.1%
WACC
11.2%
ROIC − WACC
-43.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (6)
- EPS shows upward trend
- Price CAGR 15.36%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 88% Buy
Fallido (9)
- ROIC -32.1%
- P/B Ratio 3.34
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -37.6%
- Earnings Surprise avg -14.9%
- Share Dilution 11.5%
- Piotroski F-Score 1/9
No disponible (12)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director | 57 |
| Mr. Andrew L. Guggenhime M.B.A. | President & CFO | 57 |
| Mr. James T. Wassil M.B.A., M.S. | Executive VP & COO | 56 |
| Mr. Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 43 |
| Mr. Harp Dhaliwal M.B.A. | Chief Technical Operations Officer | 52 |
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research | 61 |
| Ms. Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Jeff Macdonald | Executive Director of Investor Relations | - |
| Ms. Whitney Jones | Chief People Officer | - |
| Ms. Janet Graesser | Senior Vice President of Corporate Affairs | - |
Riesgo de Auditoría
3
Riesgo del Consejo
6
Riesgo de Compensación
8
Riesgo de Derechos del Accionista
8
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for PCVX, sourced from Markets Gazette.